Guardant Health Director Tariq Musa Reports Equity Transactions Including RSU Vesting and Share Sale on NASDAQ

Equity Acquisition via Restricted Stock Unit Vesting by Director Tariq Musa

On July 15, 2026, Tariq Musa, a director at Guardant Health, Inc., acquired 250 common shares through the vesting of previously granted restricted stock units. The RSU award was initially granted on March 6, 2023, as part of the company's equity compensation plan for board members. The vesting schedule spans four years, beginning with a 25% cliff vesting on March 15, 2024, followed by monthly vesting of the remaining 75% over the next three years.

This acquisition reflects routine equity compensation delivery to the director, consistent with the terms of the RSU award approved by shareholders or compensation committees. The shares vested were received without cost to Musa, in line with standard RSU practices where shares are granted upon fulfillment of service or time-based conditions.

Subsequent Sale of Shares Following RSU Vesting

The day after vesting, on July 16, 2026, Musa sold 116 shares of Guardant Health common stock at $163.29 per share. This sale partially reduced his direct ownership while generating proceeds from the vested shares. The timing suggests the sale may have been executed under a predetermined trading plan or as part of portfolio management decisions.

The sale price provides a market valuation benchmark for Guardant Health shares on that date. Partial liquidation of newly vested equity is common among directors and executives to diversify holdings or raise capital, while retaining a significant equity stake. After this transaction, Musa’s direct ownership stands at 11,182 shares.

Overview of Guardant Health’s Business and Market Position

Guardant Health, Inc. operates in the diagnostics and precision medicine space, specializing in oncology and broader healthcare diagnostics. The company develops blood-based tests and diagnostic solutions that detect cancer and other diseases through genomic and molecular analysis. Its business model focuses on proprietary testing platforms and diagnostic services, generating revenue from testing fees and companion diagnostics.

Guardant Health emphasizes liquid biopsy technology, which detects circulating tumor DNA and biomarkers in blood samples, offering advantages over traditional tissue biopsies. The company serves markets including oncology screening, treatment monitoring, and minimal residual disease detection, positioning itself in the expanding precision medicine and early cancer detection sectors. Increasing adoption of molecular testing by healthcare providers continues to drive investor interest in this diagnostics segment.

Director Tariq Musa’s Beneficial Ownership and Shareholding Details

Following these transactions, Tariq Musa holds 11,182 shares of Guardant Health common stock directly. This figure excludes any indirect holdings through family, trusts, or other entities. His ownership is registered solely in his name without indirect or joint arrangements.

The size of Musa’s shareholding aligns with typical director equity stakes at NASDAQ-listed healthcare companies. Equity ownership requirements and compensation programs for directors aim to align their interests with shareholders, promoting stewardship and long-term value creation. Musa’s transactions exemplify routine equity compensation vesting and partial share liquidation among corporate directors.

Details of the Restricted Stock Unit Vesting Schedule

The RSU award underlying the 250 shares vested on July 15, 2026, was granted on March 6, 2023. The vesting schedule includes a 25% cliff vesting on March 15, 2024, approximately one year after grant, followed by monthly vesting of the remaining 75% over three years. This tiered vesting approach balances immediate equity recognition with retention incentives.

The monthly vesting ensures steady equity compensation delivery through July 2027, contingent on Musa’s continued director status. This structure distributes equity awards in smaller portions over time rather than large periodic tranches, supporting ongoing alignment and retention.

Rule 10b5-1 Trading Plan Compliance

The disclosure indicates that Musa’s transactions were conducted pursuant to a contract, instruction, or written plan intended to comply with Rule 10b5-1(c). This suggests the trades were executed under a pre-established trading plan designed to comply with insider trading regulations. Rule 10b5-1 plans allow insiders to trade shares according to predetermined instructions, mitigating concerns about trading on material non-public information.

Utilizing a Rule 10b5-1 plan provides regulatory clarity and governance assurance, demonstrating adherence to insider trading laws. This framework helps maintain market integrity and investor confidence by ensuring transparent and compliant insider transactions.

Director Role and Corporate Governance Significance

Tariq Musa’s role as a Guardant Health director involves oversight of management, strategic guidance, risk management, and shareholder value enhancement. Equity ownership by directors, whether via vesting awards or market transactions, signals alignment with shareholder interests and commitment to the company.

The disclosed transactions reflect ongoing equity compensation processes and active board member participation in the company’s equity structure. Insider trades are routinely reported to provide investors with insights into insider sentiment and company valuation. Musa’s combined vesting and sale transactions are consistent with standard equity compensation administration and personal portfolio management among directors of publicly traded healthcare firms.

Transaction Filing and Legal Representation

John G. Saia, acting as attorney-in-fact for Tariq Musa, executed the disclosure documents on July 16, 2026. Delegating filing responsibilities to legal counsel is a common practice that ensures accurate and timely reporting while maintaining insider accountability. This attorney-in-fact role does not affect the substance or obligations of the insider transactions.

The disclosure filing coincided with the share sale date, complying with regulatory mandates requiring insider transaction reports within two business days. This timely filing reflects adherence to Securities Exchange Act Section 16 reporting requirements for directors and officers of NASDAQ-listed companies.

Investor Insight and Continuous Disclosure Monitoring

Investors monitoring insider activity at Guardant Health can track future transactions by Tariq Musa and other insiders through regulatory filings. Changes in director shareholdings via vesting, purchases, or sales offer insights into insider confidence, liquidity needs, and investment strategies. Accumulation of shares may indicate positive outlooks, while sales might reflect diversification or personal financial planning unrelated to company fundamentals.

This disclosure enhances transparency into Guardant Health’s insider trading and capital structure. Investors conducting due diligence may analyze historical insider trading trends, shareholding concentrations, and equity compensation patterns to better understand insider perspectives on company strategy and prospects. Insider transactions should be considered alongside broader company performance and market conditions for informed investment decisions.